Mutated citrullinated vimentin antibodies in rheumatoid arthritis

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 66-73

  Tesija Kuna, Andrea ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Anti mutated citrullinated vimentin antibodies; Citrullinated peptides; Mutated citrullinated vimentin; Rheumatoid arthritis

Indexed keywords

ANTIBODY; AURANOFIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; VIMENTIN; VIMENTIN ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN RECOGNITION; APOPTOSIS; AREA UNDER THE CURVE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MACROPHAGE; PHENOTYPE; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MUTATION; VIMENTIN;

EID: 82955220304     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.020     Document Type: Review

References (97)

1. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672.
2. Scott D.I., Wolfe F., Huizinga T.W.J. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
3. O'Dell J.R. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004, 350:2591-2602.
4. Visser H., le Cessie S., Vos K., Breedveld F.C., Hazes J.M.W. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365.
5. Tighe H., Carson D.A. Rheumatoid factor. Kelley's Textbook of Rheumatology 2005, Vol I:301-310. Elsevier Saunders, Chapter 19. 7th Edition.
6. Dörner T., Egerer K., Feist E., Burmester G.R. Rheumatoid factor revisited. Rheumatology 2004, 16:246-253.
7. Steiner G., Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 2002, 4(Suppl. 2):S1-S5.
8. Schellekens G.A., de Jong B.A.W., van den Hoogen F.H.J., van de Putte L.B.A., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
9. Nijenhuis S., Zendman A.J., Vossenaar E.R., Pruijn G.J., vanVenrooij W.J. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004, 350:17-34.
10. Egerer K., Feist E., Burmester G.R. The serological diagnosis of rheumatoid arthritis. Antibodies to citrullinated antigens. Dtsch Arztebl Int 2009, 106(10):159-163.
11. Tesija-Kuna A., Zirovic M. Antibodies to citrullinated proteins/peptides in rheumatoid arthritis: what have we learned so far?. Biochemia Medica 2008, 18(3):275-290.
12. Avouac J., Gossec L., Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006, 65:845-851.
13. Riedmann J.P., Munoz S., Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis - a systematic review. Clin Exp Rheumatol 2005, 23(Suppl. 39):S69-S76.
14. Conrad K., Roggenbuck D., Reinhold D., Dörner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev 2010, 431-435.
15. Van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 2004, 50:709-715.
16. Raza K., Breese M., Nightingale P., et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005, 32:231-238.
17. Rönnelid J., Wick M.C., Lampa J., et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749.
18. Syversen S.W., Gaarder P.I., Goll G.L., et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217.
19. Aletaha D., Neogi T., Silman A.J., et al. Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010, 62:2569-2581.
20. Masson-Bessiere C., Sebbag M., Durieux J.J., et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000, 119:544-552.
21. Chapuy-Regaud S., Sebbag M., Baeten D., et al. Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. J Immunol 2005, 174:5057-5064.
22. Koivula M.K., Savolainen E., Kaipiainen-Seppänen O., et al. Sensitivity and specificity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series. Rheumatology 2008, 47:656-659.
23. Vossenaar E.R., Despres N., Lapointe E., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6(2):R142-R150.
24. Chang X., Yamada R., Suzuki A., Kochi Y., Sawada T., Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 2005, 44(11):1374-1382.
25. Kinloch A., Tatzer V., Wait R., et al. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1421-R1429.
26. Pratesi F., Tommasi C., Anzilotti C., Chimenti D., Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54(3):733-741.
27. Despres N., Boire G., Lopez-Longo F.J., Menard H.A. The Sa system: A novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994, 21:1027-1033.
28. Menard H.A., Lapointe E., Rochdi M.D., Zhou Z.J. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000, 2:429-432.
29. El-Gabalawy H.S., Wilkins J.A. Anti-Sa antibodies: prognostic and pathogenic significance to rheumatoid arthritis. Arthritis Res Ther 2004, 6:86-89.
30. Vossenaar E.R., Despres N., Lapointe E., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6(2):R142-R150.
31. Strelkov S.V., Herrmann H., Aebi U. Molecular architecture of intermediate filaments. Bioassays 2003, 25:243-251.
32. Meyer L.H. The role of mesenchymal cells in the pathophysiology of inflammatory arthritis. Best Pract Res Clin Rheumatol 2006, 20:969-981.
33. Bang H., Egerer K., Gauliard A., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511.
34. Vossenar E.R., Radstake T.R., van der Heijden A., et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004, 63:373-381.
35. György B., Tóth E., Tarcsa E., Falus A., Buzás E.I. Citrullination: A postranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38:1662-1677.
36. Luime J.J., Colin E.M., Hazes J.M.W., Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serologic marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010, 69:337-344.
37. Soos L., Szekanecz Z., Szabo Z., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007, 34:1658-1663.
38. Poulsom H., Charles P.J. Antibodies to citrullinated vimentin are specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allerg Immunol 2008, 34:4-10.
39. Sghiri R., Bouajina E., Bargaoui D., et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int 2008, 29:59-62.
40. Roland P.N., Grootenboer Mignot S., Bruns A., et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008, 10:R142.
41. Keskin G., Inal A., Keskin D., et al. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis. Protein Pept Lett 2008, 15:314-317.
42. Bizzaro N., Tonutti E., Tozzoli R., Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007, 53(8):1527-1533.
43. Damjanovska L., Thabet M.M., Levarth E.W.N., et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010, 69:730-732.
44. Liu X., Jia R., Zhao J., Li Z. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol 2009, 36(6):1-6.
45. Mathsson L., Mullazehi M., Wick M.C., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008, 58:36-45.
46. Innala L., Kokkonen H., Eriksson C., Jiddell E., Berglin E., Rantapaa-Dahlqvist S. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008, 35:1-7.
47. Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119.
48. Wagner E., Skoumal M., Bayer P.M., Klaushofer K. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 2009, 29:1315-1321.
49. Mansour H.E., Metwaly K.M., Hassan I., Elshamy H.A.A., Elbeblawy M.M.S. Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: Diagnostic value, association with radiological damage and axial skeleton affection. Clin Med Insights: Arthritis Musculoskelet Disord 2010, 3:33-42.
50. Coenen D., Verschueren P., Westhovens R., Bossuyt Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53(3):498-504.
51. Sghiri R., Khalifa O., Bouajina E., et al. Presence and diagnostic performances of IgA class antibodies to mutated citrullinated vimentin in rheumatoid arthritis (Letter to the Editor). Joint Bone Spine 2010, 77:277-280.
52. Qin X., Deng Y., Xu J., Li T.J., Li S., Zhao J.M. Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int Available on, (published online). http://www.springerlink.com/content/a0l10100426vu172/fulltext.pdf.
53. Pruijn G.J.M., Wiik A., van Venrooij The use of citrullinated peptides and proteins for diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010, 12:203.
54. Svärd A., Kastbom A., Söderlin M.K., Reckner-Olsson A., Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 2011, 38:1265-1272.
55. Engelmann R., Brandt J., Eggert M., et al. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders. J Rheumatol 2009, 36:2670-2674.
56. Engelmann R., Brandt J., Eggert M., et al. IgG1 and IgG4 are the predominant subclass among auto-antibodies against two citrullinated antigen sin RA. Rheumatology 2008, 47:1489-1492.
57. Renger F., Bang H., Fredenhagen G., et al. Immediate determination of ACPA and rheumatoid factor - a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay. Arthritis Res Ther 2010, 12:R120.
58. Ursum J., Nielen M.M.J., van Schaardenburg D., et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008, 10:R12.
59. Turesson C., Bergström U., Jacobsson L.T.H., Truedsson L., Berglund G., Saxne T. Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis. Ann Rheum Dis 2011, 70:520-522.
60. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
61. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
62. Van der Linden M.P.M., van der Woude D., Ioan-Facsinay A., et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009, 60:2232-2241.
63. Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089.
64. Forslind K., Ahlmen M., Eberhardt K., Hafström I., Svensson B. for the BARFOT study group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63:1090-1095.
65. Niewold T.B., Harrison M.J., Paget S.A. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. Q J Med 2007, 100:193-201.
66. Landman T., Kehl G., Bergner R. The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis. Clin Rheum 2010, 29(12):1449-1453.
67. Markatseli T.E., Voulgari P.V., Alamanos Y., Drosos A.A. Prognostic factors of radiological damage in rheumatoid arthritis: a 10-year retrospective study. J Rheumatol 2011, 38(1):44-52.
68. Syversen S.W., Goll G.L., van der Heijde D., et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010, 69:345-351.
69. van Gaalen F.A., van Aken J., Huizinga T.W., et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004, 50:2113-2121.
70. Berglin E., Padyukov L., Sundin U., et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigen is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R303-R308.
71. Irigoyen P., Lee A.T., Wener M.H., et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005, 52:3813-3818.
72. de Vries R.R.P., Huizinga T.W.J., Toes R.E.M. Redefining the HLA and RA association: To be or not to be anti-CCP positive. J Autoimmun 2005, 25:21-25.
73. Goldbach-Mansky R., Lee J., McCoy A., et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000, 2:236-243.
74. Hill J.A., Southwood S., Sette A., Jevnikar A.M., Bell D.A., Cairns E. The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 171:538-541.
75. Begovich A.B., Carlton V.E., Honigberg L.A., et al. A missense single-nucleotide polymorphism in a gene encoding protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-337.
76. Hinks A., Worthington J., Thomson W. The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. Rheumatology 2006, 45:365-368.
77. Hinks A., Barton A., John S., et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005, 52:1694-1699.
78. Orozco G., Sanchez E., Gonzalez-Gay M.A., et al. Association of a functional single-nucleotide polymorphism of PTPN22 encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005, 52:219-224.
79. Mediwake R., Isenberg D.A., Schellekens G.A., van Venrooij W.J. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001, 60:67-68.
80. Brickmann K., Yazdani-Biuki B.J., Müller T., Graninger W.B., Brezinschek H.P. Anti-mutated-citrullinated vimentin antibodies (MCV) in psoriatic arthritis (Abstract. Ann Rheum Dis 2006, 65(Suppl. II):648.
81. Tesija-Kuna A., Grazio S., Miler M., Vukasovic I., Peric P., Vrkic N. Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clin Rheumatol 2010, 29:487-493.
82. Alenius G.M., Berglin E., Rantapää-Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006, 65:398-400.
83. Inanc N., Dalkilic E., Kamali S., et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007, 26:17-23.
84. Bogliolo L., Alpini C., Caporali R., Scirè C.A., Moratti R., Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005, 32:511-515.
85. Cruyssen B.V., Hoffman I.E.A., Zmierczak H., et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005, 64:1145-1149.
86. Vannini A., Cheung K., Fusconi M., et al. Anti-CCP2 positivity in non rheumatoid arthritis disease samples: citrulline dependent or not?. Ann Rheum Dis 2007, 66:511-516.
87. Lima I., Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases-a systematic review. Clin Rheumatol 2010, 29(12):1345-1351.
88. Avcin T., Cimaz R., Falcini F., et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611.
89. Low J.M., Chauhan A.K., Kietz D.A., Daud U., Pepmueller P.H., Moore T.L. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004, 31:1829-1833.
90. Machado S.H., von Mühlen C.A., Brenol J.C., Bisotto L., Xavier R.M. The prevalence of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. J Pediatr (Rio J) 2005, 81:491-494.
91. Van Rossum M., van Soesbergen R., de Kort S., et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile rheumatoid arthritis. J Rheumatol 2003, 30:825-828.
92. Hassfeld W.G., Vinje O., König K., Bayer P.M., Förre Ö., Dunky A. Autoantibodies to mutated citrullinated vimentin in juvenile rheumatoid arthritis. Ann Rheum Dis 2006, 65(Suppl. II):439.
93. Kuna Tesija A., Lamot L., Miler M., Harjacek M., Simundic A.M., Vrkic N. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 2009, 47(12):1525-1530.
94. Bang H, Luthke K, Gauliard A, et al. Mutated citrullinated vimentin as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Program and abstracts of EULAR 2006: 7th Annual European Congress of Rheumatology; June 21-24, 2006; Amsterdam, The Netherlands. Abstract THU0093.
95. Vossenaar E.R., van Venrooij W.J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004, 6:107-111.
96. Vossenaar E.R., Zendman A.J.W., van Venrooij W.J. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther 2004, 6:1-5.
97. Richter J., Benson V., Grobarova V., et al. CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. Clin Immunol 2010, 136:139-147.